Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerard Morton

Showing results (81-90 of 122) with videos related to

Pageof 13
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 9, 2020
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 GyGerard Morton, Merrylee McGuffin, Hans T Chung, et al.
British Journal of Cancer|March 30, 2018
The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiationChristopher J D Wallis, Gerard Morton, Sender Herschorn, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 9, 2016
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5GyGerard Morton, Hans T Chung, Merrylee McGuffin, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 23, 2021
Metastatic progression following multimodal therapy for unfavorable-risk prostate cancerDavid Guy, Rachel Glicksman, Roger Buckley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 15, 2024
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year updateJohn M Hudson, Andrew Loblaw, Merrylee McGuffin, et al.
Brachytherapy|July 26, 2006
Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocolMichael T Gillin, Bernadine F Dunning, Colleen A Lawton, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 29, 2021
Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trialRachel M Glicksman, Andrew Loblaw, Gerard Morton, et al.
Translational Oncology|March 10, 2015
Quantitative ultrasound spectroscopic imaging for characterization of disease extent in prostate cancer patientsAli Sadeghi-Naini, Ervis Sofroni, Naum Papanicolau, et al.
The Journal of Urology|August 27, 2021
Radiation Oncologist Consultations Prior to Radical Prostatectomy: Disparities and OpportunitiesMark T Corkum, D Andrew Loblaw, Gerard Morton, et al.
International Journal of Radiation Oncology, Biology, Physics|August 17, 2025
Bowel bag dosimetric parameters for ultrahypofractionated pelvic elective nodal irradiation in prostate cancerWee Loon Ong, Melanie Davidson, Matt Wronski, et al.
Pageof 13

Showing results (81-90 of 122) with videos related to

Sort By:
Pageof 13
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 9, 2020
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 GyGerard Morton, Merrylee McGuffin, Hans T Chung, et al.
British Journal of Cancer|March 30, 2018
The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiationChristopher J D Wallis, Gerard Morton, Sender Herschorn, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 9, 2016
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5GyGerard Morton, Hans T Chung, Merrylee McGuffin, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 23, 2021
Metastatic progression following multimodal therapy for unfavorable-risk prostate cancerDavid Guy, Rachel Glicksman, Roger Buckley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 15, 2024
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year updateJohn M Hudson, Andrew Loblaw, Merrylee McGuffin, et al.
Brachytherapy|July 26, 2006
Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocolMichael T Gillin, Bernadine F Dunning, Colleen A Lawton, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 29, 2021
Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trialRachel M Glicksman, Andrew Loblaw, Gerard Morton, et al.
Translational Oncology|March 10, 2015
Quantitative ultrasound spectroscopic imaging for characterization of disease extent in prostate cancer patientsAli Sadeghi-Naini, Ervis Sofroni, Naum Papanicolau, et al.
The Journal of Urology|August 27, 2021
Radiation Oncologist Consultations Prior to Radical Prostatectomy: Disparities and OpportunitiesMark T Corkum, D Andrew Loblaw, Gerard Morton, et al.
International Journal of Radiation Oncology, Biology, Physics|August 17, 2025
Bowel bag dosimetric parameters for ultrahypofractionated pelvic elective nodal irradiation in prostate cancerWee Loon Ong, Melanie Davidson, Matt Wronski, et al.
Pageof 13